Valerie Neff Newitt
November 2026—A 2024 outbreak of Candidozyma auris at Harborview Medical Center in Seattle made clear the efficacy of high-throughput PCR screening in containing a C. auris outbreak. At Harborview, it did so before the onset of a single clinical infection.
It was one of Washington State’s first hospital outbreaks due to C. auris, occurring one year after its first detection in Washington in 2023. “I think we were the 29th state in the country to have C. auris,” says Alex Greninger, MD, PhD, MS, MPhil, head of the Division of Infectious Disease Diagnostics, Department of Laboratory Medicine and Pathology, and the Larry Corey endowed professor of laboratory medicine and pathology, University of Washington School of Medicine.
During the six-month, multi-hospital unit outbreak at the 500-bed Harborview, the laboratory transitioned from culture-based screening to low-throughput PCR and then to high-throughput PCR screening via a laboratory-developed test.
“Once they wanted to start doing full hospital screening as opposed to just contact tracing, it became clear we needed a high-throughput PCR assay. It was a huge turning point,” says Emily Helm, MD, PhD, a resident in the Department of Pathology and Laboratory Medicine. She and Dr. Greninger are among the coauthors who reported the containment of the outbreak in a recently published article (Bryson-Cahn C, et al. Clin Infect Dis. Published online Aug. 19, 2026. doi:10.1093/cid/ciag493).
Of 29 patients who were found to be colonized, “no one had a bloodstream infection. No antifungals were given,” Dr. Greninger says. The point: “It’s possible to deal with health-care-acquired infections if we can get the testing fast and cheap enough. That’s a proven principle.”
In this case and others, what makes the fast response possible, he says, is the capital equipment acquired during the pandemic.
“Although it seems everyone is in the business of re-legislating COVID these days, we don’t have to give back the science, and we don’t have to give back the investments we made. So we’re able to take that capital investment and turn it into something that’s pretty cheap and deliver a same-day or overnight PCR turnaround time on a large number of samples,” Dr. Greninger says, “which is what is required if you want to stop an outbreak.”
Many laboratories that had to do high-throughput PCR testing for SARS-CoV-2 “are sitting on an instrument, like a Roche Cobas, where they have the ability to add primers and probes. That lowers the bar significantly to doing laboratory-developed tests,” he notes.
“All the development work has been done for you,” he says. “You can basically start at validation, and that is a very different world than pre-COVID.” It’s still not easy, he adds, “but it’s a lot easier than it was six or seven years ago.”
With its high-throughput PCR setup on its own Roche Cobas instrument, he says, the UW laboratory was able to screen “everyone in the hospital and everyone coming into the hospital, and within four months of doing that testing, we had two negative screens throughout the entire hospital, which allowed us to declare the outbreak over.”
The first case at Harborview was discovered on a urine culture sent for a fever workup, Dr. Helm says. That positive result prompted an investigation, including testing of patients who had been in the same unit, and it was learned that the patient who had been in the same room immediately prior to the first patient who tested positive had multiple health-care-associated contacts and risk factors for C. auris.
Dr. Greninger calls the detection of the first patient “a lucky detection.”
The patient was 37 years old with no past medical history, admitted for cardiac arrest. During week three of his hospitalization, a urine culture sent from a Foley catheter for the fever workup grew a pure culture of more than 100,000 CFU of yeast, identified as C. auris by MALDI-TOF mass spectrometry. “We just worked up all the Candidas to speciate them fully because of the concern for C. auris,” Dr. Greninger says of the laboratory’s routine protocol.
At the start of the outbreak, testing was done in the state public health laboratory and in-house. In-house culture testing expanded but was limited, and thus a PCR-based LDT was validated using the open channel of the BD Max platform. The assay was used from outbreak day 25 to day 69 concurrently with culture screening. By week 10, they validated the LDT using the open channel of the Cobas 8800. Its limit of detection was less than 30 CFU/mL.
No high-throughput PCR assays are currently FDA cleared for C. auris detection.
“It’s this weird world where in two weeks we could bring up a new test, do 9,000 tests with it, and stop an outbreak,” Dr. Greninger says. “Yet companies looking at the market through the conventional FDA pathway could reasonably conclude there’s not really a reimbursement. We’re not going to do it.” Thus the importance of keeping the LDT pathways open, he adds.
He calls it a “gap in the U.S. when it comes to this type of [infectious disease] testing.”
Drs. Greninger and Helm and their coauthors report that the high-throughput testing incurred significant laboratory costs: $310,000 in reagents and a total of $351,000 when accounting for labor. Low-throughput PCR had the highest cost per test due to manual batch limits, they write.
How best to screen for C. auris is far from settled. Public health guidelines generally call for a targeted approach. A UW study of Harborview Medical Center patients used the universal admission screening implemented in July 2024 in response to the institution’s first identified hospital-associated transmission to determine if the Centers for Disease Control and Prevention guidance describing those at risk for C. auris would capture the extent of C. auris colonization in the general population.
“We were just looking at who we detect at admission screening,” Dr. Greninger, a coauthor, says (Smith AGC, et al. Clin Infect Dis. 2026; 83[3]:438–441). “Would you have screened them if you had been following public health criteria?”
The answer, they found, was no. The majority of positive colonization cases would not have been tested or identified under current public health guidance, they report.
Among 22,742 total patient admission screens, 25 patients tested positive for C. auris colonization by composite axillary and groin swab (median time from arrival to collection of the swab: nine hours). All tested positive by PCR assay. Only five of the 25 met the Washington State Department of Health recommended criteria for high-risk surveillance testing, which are adapted from CDC recommendations.
“It highlights that what we’re doing for targeted screening now misses a lot of cases,” Dr. Helm says, “and that having the capacity to do broader screening is important.”
“We have the technology,” she adds, “but not always the money.”
With 80 percent of those in whom C. auris colonization was detected not meeting public health screening criteria, Dr. Greninger says, “the findings mean we don’t know who to screen. If you don’t know who to screen, then you have to go on, ‘Who’s going to get sick from it?’ And those are usually your ICU patients. So maybe a more aggressive screening algorithm on transfer to the ICU could be helpful.”
Dr. Greninger is quick to point out that laboratory testing alone can’t halt an outbreak. “It’s a real intensive process to clean a room for one of these organisms. The lab testing helps to focus that intensity,” he says, adding, “But, boy, is that challenging work.”
And of the laboratory team that has the expertise and dedication to validate an LDT so quickly, he says: “I can’t speak highly enough of our staff and how much they get up and come here to make the world better. To be able to offer this method takes extra work, and they’re not getting extra pay for it. It’s just their wanting to do the best they can with the tools available.”
He calls the work to end an outbreak, like so much else in life, a team sport. “It’s infection prevention and it’s the laboratory. One without the other wouldn’t get it done.”
Valerie Neff Newitt is a writer in Audubon, Pa.